Service & Software

Global Peptide Synthesis CDMO Services Market Outlook, In‑Depth Analysis & Forecast to 2031

Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Peptide Synthesis CDMO Services market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Bachem
CordenPharma
PolyPeptide
AmbioPharm
Genscript
Thermo Fisher
USV Peptides
Bio Basic
ScinoPharm
JPT
CBL
Piramal Pharma
CPC Scientific
Creative Peptides
Chinese Peptide Company
ChengDu ShengNuo Biotec
AppTec Co., Ltd.
GL Biochem
Segment by Type
GMP Services
Non-GMP Services
Segment by Application
Commercial
Scientific Research
Other
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Peptide Synthesis CDMO Services study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Peptide Synthesis CDMO Services: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Peptide Synthesis CDMO Services Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 GMP Services
1.2.3 Non-GMP Services
1.3 Market Segmentation by Application
1.3.1 Global Peptide Synthesis CDMO Services Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Commercial
1.3.3 Scientific Research
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Peptide Synthesis CDMO Services Revenue Estimates and Forecasts 2020-2031
2.2 Global Peptide Synthesis CDMO Services Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Peptide Synthesis CDMO Services Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Peptide Synthesis CDMO Services Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 GMP Services Market Size by Players
3.3.2 Non-GMP Services Market Size by Players
3.4 Global Peptide Synthesis CDMO Services Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Peptide Synthesis CDMO Services Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Peptide Synthesis CDMO Services Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Peptide Synthesis CDMO Services Market Size by Type (2020-2031)
6.4 North America Peptide Synthesis CDMO Services Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Peptide Synthesis CDMO Services Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Peptide Synthesis CDMO Services Market Size by Type (2020-2031)
7.4 Europe Peptide Synthesis CDMO Services Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Peptide Synthesis CDMO Services Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Peptide Synthesis CDMO Services Market Size by Type (2020-2031)
8.4 Asia-Pacific Peptide Synthesis CDMO Services Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Peptide Synthesis CDMO Services Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Peptide Synthesis CDMO Services Market Size by Type (2020-2031)
9.4 Central and South America Peptide Synthesis CDMO Services Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Peptide Synthesis CDMO Services Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Peptide Synthesis CDMO Services Market Size by Type (2020-2031)
10.4 Middle East and Africa Peptide Synthesis CDMO Services Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Peptide Synthesis CDMO Services Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Bachem
11.1.1 Bachem Corporation Information
11.1.2 Bachem Business Overview
11.1.3 Bachem Peptide Synthesis CDMO Services Product Features and Attributes
11.1.4 Bachem Peptide Synthesis CDMO Services Revenue and Gross Margin (2020-2025)
11.1.5 Bachem Peptide Synthesis CDMO Services Revenue by Product in 2024
11.1.6 Bachem Peptide Synthesis CDMO Services Revenue by Application in 2024
11.1.7 Bachem Peptide Synthesis CDMO Services Revenue by Geographic Area in 2024
11.1.8 Bachem Peptide Synthesis CDMO Services SWOT Analysis
11.1.9 Bachem Recent Developments
11.2 CordenPharma
11.2.1 CordenPharma Corporation Information
11.2.2 CordenPharma Business Overview
11.2.3 CordenPharma Peptide Synthesis CDMO Services Product Features and Attributes
11.2.4 CordenPharma Peptide Synthesis CDMO Services Revenue and Gross Margin (2020-2025)
11.2.5 CordenPharma Peptide Synthesis CDMO Services Revenue by Product in 2024
11.2.6 CordenPharma Peptide Synthesis CDMO Services Revenue by Application in 2024
11.2.7 CordenPharma Peptide Synthesis CDMO Services Revenue by Geographic Area in 2024
11.2.8 CordenPharma Peptide Synthesis CDMO Services SWOT Analysis
11.2.9 CordenPharma Recent Developments
11.3 PolyPeptide
11.3.1 PolyPeptide Corporation Information
11.3.2 PolyPeptide Business Overview
11.3.3 PolyPeptide Peptide Synthesis CDMO Services Product Features and Attributes
11.3.4 PolyPeptide Peptide Synthesis CDMO Services Revenue and Gross Margin (2020-2025)
11.3.5 PolyPeptide Peptide Synthesis CDMO Services Revenue by Product in 2024
11.3.6 PolyPeptide Peptide Synthesis CDMO Services Revenue by Application in 2024
11.3.7 PolyPeptide Peptide Synthesis CDMO Services Revenue by Geographic Area in 2024
11.3.8 PolyPeptide Peptide Synthesis CDMO Services SWOT Analysis
11.3.9 PolyPeptide Recent Developments
11.4 AmbioPharm
11.4.1 AmbioPharm Corporation Information
11.4.2 AmbioPharm Business Overview
11.4.3 AmbioPharm Peptide Synthesis CDMO Services Product Features and Attributes
11.4.4 AmbioPharm Peptide Synthesis CDMO Services Revenue and Gross Margin (2020-2025)
11.4.5 AmbioPharm Peptide Synthesis CDMO Services Revenue by Product in 2024
11.4.6 AmbioPharm Peptide Synthesis CDMO Services Revenue by Application in 2024
11.4.7 AmbioPharm Peptide Synthesis CDMO Services Revenue by Geographic Area in 2024
11.4.8 AmbioPharm Peptide Synthesis CDMO Services SWOT Analysis
11.4.9 AmbioPharm Recent Developments
11.5 Genscript
11.5.1 Genscript Corporation Information
11.5.2 Genscript Business Overview
11.5.3 Genscript Peptide Synthesis CDMO Services Product Features and Attributes
11.5.4 Genscript Peptide Synthesis CDMO Services Revenue and Gross Margin (2020-2025)
11.5.5 Genscript Peptide Synthesis CDMO Services Revenue by Product in 2024
11.5.6 Genscript Peptide Synthesis CDMO Services Revenue by Application in 2024
11.5.7 Genscript Peptide Synthesis CDMO Services Revenue by Geographic Area in 2024
11.5.8 Genscript Peptide Synthesis CDMO Services SWOT Analysis
11.5.9 Genscript Recent Developments
11.6 Thermo Fisher
11.6.1 Thermo Fisher Corporation Information
11.6.2 Thermo Fisher Business Overview
11.6.3 Thermo Fisher Peptide Synthesis CDMO Services Product Features and Attributes
11.6.4 Thermo Fisher Peptide Synthesis CDMO Services Revenue and Gross Margin (2020-2025)
11.6.5 Thermo Fisher Recent Developments
11.7 USV Peptides
11.7.1 USV Peptides Corporation Information
11.7.2 USV Peptides Business Overview
11.7.3 USV Peptides Peptide Synthesis CDMO Services Product Features and Attributes
11.7.4 USV Peptides Peptide Synthesis CDMO Services Revenue and Gross Margin (2020-2025)
11.7.5 USV Peptides Recent Developments
11.8 Bio Basic
11.8.1 Bio Basic Corporation Information
11.8.2 Bio Basic Business Overview
11.8.3 Bio Basic Peptide Synthesis CDMO Services Product Features and Attributes
11.8.4 Bio Basic Peptide Synthesis CDMO Services Revenue and Gross Margin (2020-2025)
11.8.5 Bio Basic Recent Developments
11.9 ScinoPharm
11.9.1 ScinoPharm Corporation Information
11.9.2 ScinoPharm Business Overview
11.9.3 ScinoPharm Peptide Synthesis CDMO Services Product Features and Attributes
11.9.4 ScinoPharm Peptide Synthesis CDMO Services Revenue and Gross Margin (2020-2025)
11.9.5 ScinoPharm Recent Developments
11.10 JPT
11.10.1 JPT Corporation Information
11.10.2 JPT Business Overview
11.10.3 JPT Peptide Synthesis CDMO Services Product Features and Attributes
11.10.4 JPT Peptide Synthesis CDMO Services Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 CBL
11.11.1 CBL Corporation Information
11.11.2 CBL Business Overview
11.11.3 CBL Peptide Synthesis CDMO Services Product Features and Attributes
11.11.4 CBL Peptide Synthesis CDMO Services Revenue and Gross Margin (2020-2025)
11.11.5 CBL Recent Developments
11.12 Piramal Pharma
11.12.1 Piramal Pharma Corporation Information
11.12.2 Piramal Pharma Business Overview
11.12.3 Piramal Pharma Peptide Synthesis CDMO Services Product Features and Attributes
11.12.4 Piramal Pharma Peptide Synthesis CDMO Services Revenue and Gross Margin (2020-2025)
11.12.5 Piramal Pharma Recent Developments
11.13 CPC Scientific
11.13.1 CPC Scientific Corporation Information
11.13.2 CPC Scientific Business Overview
11.13.3 CPC Scientific Peptide Synthesis CDMO Services Product Features and Attributes
11.13.4 CPC Scientific Peptide Synthesis CDMO Services Revenue and Gross Margin (2020-2025)
11.13.5 CPC Scientific Recent Developments
11.14 Creative Peptides
11.14.1 Creative Peptides Corporation Information
11.14.2 Creative Peptides Business Overview
11.14.3 Creative Peptides Peptide Synthesis CDMO Services Product Features and Attributes
11.14.4 Creative Peptides Peptide Synthesis CDMO Services Revenue and Gross Margin (2020-2025)
11.14.5 Creative Peptides Recent Developments
11.15 Chinese Peptide Company
11.15.1 Chinese Peptide Company Corporation Information
11.15.2 Chinese Peptide Company Business Overview
11.15.3 Chinese Peptide Company Peptide Synthesis CDMO Services Product Features and Attributes
11.15.4 Chinese Peptide Company Peptide Synthesis CDMO Services Revenue and Gross Margin (2020-2025)
11.15.5 Chinese Peptide Company Recent Developments
11.16 ChengDu ShengNuo Biotec
11.16.1 ChengDu ShengNuo Biotec Corporation Information
11.16.2 ChengDu ShengNuo Biotec Business Overview
11.16.3 ChengDu ShengNuo Biotec Peptide Synthesis CDMO Services Product Features and Attributes
11.16.4 ChengDu ShengNuo Biotec Peptide Synthesis CDMO Services Revenue and Gross Margin (2020-2025)
11.16.5 ChengDu ShengNuo Biotec Recent Developments
11.17 AppTec Co., Ltd.
11.17.1 AppTec Co., Ltd. Corporation Information
11.17.2 AppTec Co., Ltd. Business Overview
11.17.3 AppTec Co., Ltd. Peptide Synthesis CDMO Services Product Features and Attributes
11.17.4 AppTec Co., Ltd. Peptide Synthesis CDMO Services Revenue and Gross Margin (2020-2025)
11.17.5 AppTec Co., Ltd. Recent Developments
11.18 GL Biochem
11.18.1 GL Biochem Corporation Information
11.18.2 GL Biochem Business Overview
11.18.3 GL Biochem Peptide Synthesis CDMO Services Product Features and Attributes
11.18.4 GL Biochem Peptide Synthesis CDMO Services Revenue and Gross Margin (2020-2025)
11.18.5 GL Biochem Recent Developments
12 Peptide Synthesis CDMO ServicesIndustry Chain Analysis
12.1 Peptide Synthesis CDMO Services Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Peptide Synthesis CDMO Services Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Peptide Synthesis CDMO Services Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Peptide Synthesis CDMO Services Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Peptide Synthesis CDMO Services Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Peptide Synthesis CDMO Services Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Peptide Synthesis CDMO Services Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Peptide Synthesis CDMO Services Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Peptide Synthesis CDMO Services Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Peptide Synthesis CDMO Services Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Peptide Synthesis CDMO Services by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Synthesis CDMO Services as of 2024)
Table 11. Global Peptide Synthesis CDMO Services Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Peptide Synthesis CDMO Services Companies Headquarters
Table 13. Global Peptide Synthesis CDMO Services Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Peptide Synthesis CDMO Services Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Peptide Synthesis CDMO Services Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Peptide Synthesis CDMO Services Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Peptide Synthesis CDMO Services Revenue by Application (2026-2031) & (US$ Million)
Table 21. Peptide Synthesis CDMO Services High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Peptide Synthesis CDMO Services Growth Accelerators and Market Barriers
Table 25. North America Peptide Synthesis CDMO Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Peptide Synthesis CDMO Services Growth Accelerators and Market Barriers
Table 27. Europe Peptide Synthesis CDMO Services Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Peptide Synthesis CDMO Services Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Peptide Synthesis CDMO Services Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Peptide Synthesis CDMO Services Investment Opportunities and Key Challenges
Table 31. Central and South America Peptide Synthesis CDMO Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Peptide Synthesis CDMO Services Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Peptide Synthesis CDMO Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Bachem Corporation Information
Table 35. Bachem Description and Major Businesses
Table 36. Bachem Product Features and Attributes
Table 37. Bachem Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Bachem Revenue Proportion by Product in 2024
Table 39. Bachem Revenue Proportion by Application in 2024
Table 40. Bachem Revenue Proportion by Geographic Area in 2024
Table 41. Bachem Peptide Synthesis CDMO Services SWOT Analysis
Table 42. Bachem Recent Developments
Table 43. CordenPharma Corporation Information
Table 44. CordenPharma Description and Major Businesses
Table 45. CordenPharma Product Features and Attributes
Table 46. CordenPharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. CordenPharma Revenue Proportion by Product in 2024
Table 48. CordenPharma Revenue Proportion by Application in 2024
Table 49. CordenPharma Revenue Proportion by Geographic Area in 2024
Table 50. CordenPharma Peptide Synthesis CDMO Services SWOT Analysis
Table 51. CordenPharma Recent Developments
Table 52. PolyPeptide Corporation Information
Table 53. PolyPeptide Description and Major Businesses
Table 54. PolyPeptide Product Features and Attributes
Table 55. PolyPeptide Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. PolyPeptide Revenue Proportion by Product in 2024
Table 57. PolyPeptide Revenue Proportion by Application in 2024
Table 58. PolyPeptide Revenue Proportion by Geographic Area in 2024
Table 59. PolyPeptide Peptide Synthesis CDMO Services SWOT Analysis
Table 60. PolyPeptide Recent Developments
Table 61. AmbioPharm Corporation Information
Table 62. AmbioPharm Description and Major Businesses
Table 63. AmbioPharm Product Features and Attributes
Table 64. AmbioPharm Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. AmbioPharm Revenue Proportion by Product in 2024
Table 66. AmbioPharm Revenue Proportion by Application in 2024
Table 67. AmbioPharm Revenue Proportion by Geographic Area in 2024
Table 68. AmbioPharm Peptide Synthesis CDMO Services SWOT Analysis
Table 69. AmbioPharm Recent Developments
Table 70. Genscript Corporation Information
Table 71. Genscript Description and Major Businesses
Table 72. Genscript Product Features and Attributes
Table 73. Genscript Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Genscript Revenue Proportion by Product in 2024
Table 75. Genscript Revenue Proportion by Application in 2024
Table 76. Genscript Revenue Proportion by Geographic Area in 2024
Table 77. Genscript Peptide Synthesis CDMO Services SWOT Analysis
Table 78. Genscript Recent Developments
Table 79. Thermo Fisher Corporation Information
Table 80. Thermo Fisher Description and Major Businesses
Table 81. Thermo Fisher Product Features and Attributes
Table 82. Thermo Fisher Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Thermo Fisher Recent Developments
Table 84. USV Peptides Corporation Information
Table 85. USV Peptides Description and Major Businesses
Table 86. USV Peptides Product Features and Attributes
Table 87. USV Peptides Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. USV Peptides Recent Developments
Table 89. Bio Basic Corporation Information
Table 90. Bio Basic Description and Major Businesses
Table 91. Bio Basic Product Features and Attributes
Table 92. Bio Basic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Bio Basic Recent Developments
Table 94. ScinoPharm Corporation Information
Table 95. ScinoPharm Description and Major Businesses
Table 96. ScinoPharm Product Features and Attributes
Table 97. ScinoPharm Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. ScinoPharm Recent Developments
Table 99. JPT Corporation Information
Table 100. JPT Description and Major Businesses
Table 101. JPT Product Features and Attributes
Table 102. JPT Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. JPT Recent Developments
Table 104. CBL Corporation Information
Table 105. CBL Description and Major Businesses
Table 106. CBL Product Features and Attributes
Table 107. CBL Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. CBL Recent Developments
Table 109. Piramal Pharma Corporation Information
Table 110. Piramal Pharma Description and Major Businesses
Table 111. Piramal Pharma Product Features and Attributes
Table 112. Piramal Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Piramal Pharma Recent Developments
Table 114. CPC Scientific Corporation Information
Table 115. CPC Scientific Description and Major Businesses
Table 116. CPC Scientific Product Features and Attributes
Table 117. CPC Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. CPC Scientific Recent Developments
Table 119. Creative Peptides Corporation Information
Table 120. Creative Peptides Description and Major Businesses
Table 121. Creative Peptides Product Features and Attributes
Table 122. Creative Peptides Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Creative Peptides Recent Developments
Table 124. Chinese Peptide Company Corporation Information
Table 125. Chinese Peptide Company Description and Major Businesses
Table 126. Chinese Peptide Company Product Features and Attributes
Table 127. Chinese Peptide Company Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Chinese Peptide Company Recent Developments
Table 129. ChengDu ShengNuo Biotec Corporation Information
Table 130. ChengDu ShengNuo Biotec Description and Major Businesses
Table 131. ChengDu ShengNuo Biotec Product Features and Attributes
Table 132. ChengDu ShengNuo Biotec Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. ChengDu ShengNuo Biotec Recent Developments
Table 134. AppTec Co., Ltd. Corporation Information
Table 135. AppTec Co., Ltd. Description and Major Businesses
Table 136. AppTec Co., Ltd. Product Features and Attributes
Table 137. AppTec Co., Ltd. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. AppTec Co., Ltd. Recent Developments
Table 139. GL Biochem Corporation Information
Table 140. GL Biochem Description and Major Businesses
Table 141. GL Biochem Product Features and Attributes
Table 142. GL Biochem Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. GL Biochem Recent Developments
Table 144. Raw Materials Key Suppliers
Table 145. Distributors List
Table 146. Market Trends and Market Evolution
Table 147. Market Drivers and Opportunities
Table 148. Market Challenges, Risks, and Restraints
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources


List of Figures
Figure 1. Peptide Synthesis CDMO Services Product Picture
Figure 2. Global Peptide Synthesis CDMO Services Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. GMP Services Product Picture
Figure 4. Non-GMP Services Product Picture
Figure 5. Global Peptide Synthesis CDMO Services Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Commercial
Figure 7. Scientific Research
Figure 8. Other
Figure 9. Peptide Synthesis CDMO Services Report Years Considered
Figure 10. Global Peptide Synthesis CDMO Services Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Peptide Synthesis CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 12. Global Peptide Synthesis CDMO Services Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Peptide Synthesis CDMO Services Revenue Market Share by Region (2020-2031)
Figure 14. Global Peptide Synthesis CDMO Services Revenue Market Share Ranking (2024)
Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 16. GMP Services Revenue Market Share by Player in 2024
Figure 17. Non-GMP Services Revenue Market Share by Player in 2024
Figure 18. Global Peptide Synthesis CDMO Services Revenue Market Share by Type (2020-2031)
Figure 19. Global Peptide Synthesis CDMO Services Revenue Market Share by Application (2020-2031)
Figure 20. North America Peptide Synthesis CDMO Services Revenue YoY (2020-2031) & (US$ Million)
Figure 21. North America Top 5 Players Peptide Synthesis CDMO Services Revenue (US$ Million) in 2024
Figure 22. North America Peptide Synthesis CDMO Services Revenue (US$ Million) by Type (2020 - 2031)
Figure 23. North America Peptide Synthesis CDMO Services Revenue (US$ Million) by Application (2020-2031)
Figure 24. US Peptide Synthesis CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 25. Canada Peptide Synthesis CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 26. Mexico Peptide Synthesis CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 27. Europe Peptide Synthesis CDMO Services Revenue YoY (2020-2031) & (US$ Million)
Figure 28. Europe Top 5 Players Peptide Synthesis CDMO Services Revenue (US$ Million) in 2024
Figure 29. Europe Peptide Synthesis CDMO Services Revenue (US$ Million) by Type (2020-2031)
Figure 30. Europe Peptide Synthesis CDMO Services Revenue (US$ Million) by Application (2020-2031)
Figure 31. Germany Peptide Synthesis CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 32. France Peptide Synthesis CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 33. U.K. Peptide Synthesis CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 34. Italy Peptide Synthesis CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 35. Russia Peptide Synthesis CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Peptide Synthesis CDMO Services Revenue YoY (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Top 8 Players Peptide Synthesis CDMO Services Revenue (US$ Million) in 2024
Figure 38. Asia-Pacific Peptide Synthesis CDMO Services Revenue (US$ Million) by Type (2020-2031)
Figure 39. Asia-Pacific Peptide Synthesis CDMO Services Revenue (US$ Million) by Application (2020-2031)
Figure 40. Indonesia Peptide Synthesis CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 41. Japan Peptide Synthesis CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 42. South Korea Peptide Synthesis CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 43. Australia Peptide Synthesis CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 44. India Peptide Synthesis CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 45. Indonesia Peptide Synthesis CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 46. Vietnam Peptide Synthesis CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 47. Malaysia Peptide Synthesis CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 48. Philippines Peptide Synthesis CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 49. Singapore Peptide Synthesis CDMO Services Revenue (2020-2031) & (US$ Million)
Figure 50. Central and South America Peptide Synthesis CDMO Services Revenue YoY (2020-2031) & (US$ Million)
Figure 51. Central and South America Top 5 Players Peptide Synthesis CDMO Services Revenue (US$ Million) in 2024
Figure 52. Central and South America Peptide Synthesis CDMO Services Revenue (US$ Million) by Type (2020-2031)
Figure 53. Central and South America Peptide Synthesis CDMO Services Revenue (US$ Million) by Application (2020-2031)
Figure 54. Brazil Peptide Synthesis CDMO Services Revenue (2020-2025) & (US$ Million)
Figure 55. Argentina Peptide Synthesis CDMO Services Revenue (2020-2025) & (US$ Million)
Figure 56. Middle East and Africa Peptide Synthesis CDMO Services Revenue YoY (2020-2031) & (US$ Million)
Figure 57. Middle East and Africa Top 5 Players Peptide Synthesis CDMO Services Revenue (US$ Million) in 2024
Figure 58. South America Peptide Synthesis CDMO Services Revenue (US$ Million) by Type (2020-2031)
Figure 59. Middle East and Africa Peptide Synthesis CDMO Services Revenue (US$ Million) by Application (2020-2031)
Figure 60. GCC Countries Peptide Synthesis CDMO Services Revenue (2020-2025) & (US$ Million)
Figure 61. Israel Peptide Synthesis CDMO Services Revenue (2020-2025) & (US$ Million)
Figure 62. Egypt Peptide Synthesis CDMO Services Revenue (2020-2025) & (US$ Million)
Figure 63. South Africa Peptide Synthesis CDMO Services Revenue (2020-2025) & (US$ Million)
Figure 64. Peptide Synthesis CDMO Services Industry Chain Mapping
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies